Abstract
The discovery of some key molecular mechanisms underlying the dysregulation of the immune system responsible for inflammatory systemic diseases as severe as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), and Systemic Vasculitides, led to the development and subsequent introduction into clinical practice of biological drugs which are significantly improving the management of such complex disorders. This novel molecular targeted therapeutics represents in fact a valid alternative or complementary treatment to conventional immunosuppressive strategies, characterized by broad, unspecific actions and severe adverse effects. Main advantages of the use of biologic drugs reside in their steroid-sparing effect and in the ability of inducing remission of refractory disease states or curing specific organ involvements. Aim of this article is to review and briefly discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the canonical drugs.
Keywords: Belimumab, imatinib, infliximab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), systemic vasculitis, tocilizumab.
Current Drug Safety
Title:Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile
Volume: 11 Issue: 1
Author(s): Gianluca Moroncini, Lisa Albani, Lorenzo Nobili and Armando Gabrielli
Affiliation:
Keywords: Belimumab, imatinib, infliximab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), systemic vasculitis, tocilizumab.
Abstract: The discovery of some key molecular mechanisms underlying the dysregulation of the immune system responsible for inflammatory systemic diseases as severe as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), and Systemic Vasculitides, led to the development and subsequent introduction into clinical practice of biological drugs which are significantly improving the management of such complex disorders. This novel molecular targeted therapeutics represents in fact a valid alternative or complementary treatment to conventional immunosuppressive strategies, characterized by broad, unspecific actions and severe adverse effects. Main advantages of the use of biologic drugs reside in their steroid-sparing effect and in the ability of inducing remission of refractory disease states or curing specific organ involvements. Aim of this article is to review and briefly discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the canonical drugs.
Export Options
About this article
Cite this article as:
Moroncini Gianluca, Albani Lisa, Nobili Lorenzo and Gabrielli Armando, Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666151014115251
DOI https://dx.doi.org/10.2174/1574886310666151014115251 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antineoplastic Activity, Structural Modification, Synthesis and Structure-activity Relationship of Dammarane-type Ginsenosides: An Overview
Current Organic Chemistry Status Epilepticus: An Overview
Current Drug Metabolism Mechanisms of Incretin Effects on Plasma Lipids and Implications for the Cardiovascular System
Cardiovascular & Hematological Agents in Medicinal Chemistry Mixed Connective Tissue Disease (MCTD) and Undifferentiated Connective Tissue Disease (UCTD)
Current Rheumatology Reviews Recent Progress of Machine Learning in Gene Therapy
Current Gene Therapy Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment
Current Neuropharmacology Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate and Related Steroids: Their Role in Inflammatory, Allergic and Immunological Disorders
Current Drug Targets - Inflammation & Allergy Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Current Pharmaceutical Design Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets The Rationale and Development of New Drugs to Treat HIV Infection
Medicinal Chemistry Spontaneous (Autoimmune) Chronic Urticaria in Children: Current Evidences, Diagnostic Pitfalls and Therapeutic Management
Recent Patents on Inflammation & Allergy Drug Discovery Phytoestrogens: Implications in Neurovascular Research
Current Neurovascular Research Development of Infection and Inflammation Targeting Compounds
Current Radiopharmaceuticals An Overview of Published Papers and Important Developments in the Past Three Years
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry HCV-Related Transformation and New Therapeutic Strategies: An Update
Current Cancer Therapy Reviews Effectiveness of Long-Term Macrolide Therapy in Cryptogenic Organising Pneumonia
Current Respiratory Medicine Reviews Imaging Subclinical Atherosclerosis: Where Do We Stand?
Current Cardiology Reviews Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design